UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 114

Sortiert nach

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

The Lancet (British edition), 2010-10, Vol.376 (9747), p.1155-1163

2010

Volltextzugriff (PDF)

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1066-1074

2016

Volltextzugriff (PDF)

Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)

Journal of clinical oncology, 2011-03, Vol.29 (8), p.957-962

2011

Volltextzugriff (PDF)

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

Clinical cancer research, 2012-06, Vol.18 (12), p.3428-3439

2012

Volltextzugriff (PDF)

Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer

Clinical cancer research, 2010-10, Vol.16 (19), p.4899-4905

2010

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-03, Vol.18 (5), p.1415-1425

2012

Volltextzugriff (PDF)

Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4862-4866

2006

Volltextzugriff (PDF)

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)

JNCI : Journal of the National Cancer Institute, 2004-03, Vol.96 (6), p.487-488

2004

Volltextzugriff (PDF)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

International journal of gynecological cancer, 2017-07, Vol.27 (6), p.1118-1122

2017

Volltextzugriff (PDF)

18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group

Journal of clinical oncology, 2007-07, Vol.25 (21), p.3090-3095

2007

Volltextzugriff (PDF)

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

Clinical cancer research, 2004-06, Vol.10 (11), p.3919-3926

2004

Volltextzugriff (PDF)

What Surveillance Plan Should Be Advised for Patients in Remission After Completion of First-Line Therapy for Advanced Ovarian Cancer?

International journal of gynecological cancer, 2010-10, Vol.20 (11 Suppl 2), p.S27-S28

Rustin, Gordon J. S

2010

Volltextzugriff (PDF)

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Journal of clinical oncology, 2022-08, Vol.40 (22), p.2468-2478

2022

Volltextzugriff (PDF)

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

The lancet oncology, 2007-09, Vol.8 (9), p.813-821

2007

Volltextzugriff (PDF)

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

Neoplasia (New York, N.Y.), 2009-02, Vol.11 (2), p.102-125

2009

Volltextzugriff (PDF)

How to follow-up patients with epithelial ovarian cancer

Current opinion in oncology, 2010-09, Vol.22 (5), p.498-502

2010

Volltextzugriff (PDF)

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel–gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series

European journal of cancer (1990), 2010-07, Vol.46 (11), p.2020-2026

2010

Volltextzugriff (PDF)

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2815-2822

2003

Volltextzugriff (PDF)

Current controversies in the management of germ cell ovarian tumours

Current opinion in oncology, 2013-09, Vol.25 (5), p.539-545

2013

Volltextzugriff (PDF)

Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors

Journal of magnetic resonance imaging, 2007-04, Vol.25 (4), p.796-805

2007

Volltextzugriff (PDF)

Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2831-2842

2003

Volltextzugriff (PDF)

Controversies in the management of germ cell tumours of the ovary

Current opinion in oncology, 2006-09, Vol.18 (5), p.500-506

2006

Volltextzugriff (PDF)

The cost of surveillance following treatment of ovarian cancer

Gynecologic oncology, 2013-12, Vol.131 (3), p.501-502

Rustin, Gordon J.S

2013

Volltextzugriff (PDF)

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis

NMR in biomedicine, 2002-04, Vol.15 (2), p.132-142

2002

Volltextzugriff (PDF)

Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours

BJU international, 2013-04, Vol.111 (4b), p.E152-E157

2013

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(113)
Buchkapitel
(1)

Sprache

Englisch
(114)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(80)
Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Female
(63)
Oncology
(54)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Adult
(36)
Middle Aged
(30)
Male
(26)
Tumors
(25)
Chemotherapy
(24)
Treatment Outcome
(23)
Pharmacology. Drug Treatments
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Ovarian Neoplasms - Drug Therapy
(21)
Antineoplastic Agents
(19)
Ovarian Cancer
(19)
Aged
(18)
Antineoplastic Agents - Therapeutic Use
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic Markers and Long-Term Outcome After Multimodality Treatment

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

What Surveillance Plan Should Be Advised for Patients in Remission After Completion of First-Line Therapy for Advanced Ovarian Cancer?

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

How to follow-up patients with epithelial ovarian cancer

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel–gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Current controversies in the management of germ cell ovarian tumours

Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors

Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

Controversies in the management of germ cell tumours of the ovary

The cost of surveillance following treatment of ovarian cancer

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis

Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours

Suchergebnisse filtern